Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G. M. Durie, Robert Z. Orlowski

Blood (2025) 146 (21): 2507–2516.

https://doi.org/10.1182/blood.2024027962

Published: 2025

Journal Articles

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Cameron Hunter, Karthik Chetlapalli, Satoko Ito, Jan Philipp Bewersdorf, Prajwal Boddu, Sabrina Browning, Stephanie Halene, Terri Parker, Scott Huntington, Shalin Kothari, Lourdes Mendez, Natalia Neparidze, Tarsheen Sethi, Maximilian Stahl, Nikolai Podoltsev, Amer Zeidan, Rory Shallis, George Goshua

Blood (2025) 146 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2025-6208

Published: 2025

Journal Articles

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin

Francesca Albano, Sabrina Browning, Fangyong Li, Noffar Bar, Terri Parker, Tara Anderson, Erica Stevens, Jennifer VanOudenhove, Martin Matthews, Elan Gorshein, Jason Haldas, Ashita Talsania, Kert Sabbath, Stuart Seropian, Stephanie Halene, Fabiana Perna, Natalia Neparidze

Blood (2025) 146 (Supplement 1): 7578.

https://doi.org/10.1182/blood-2025-7578

Published: 2025

Journal Articles

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Blood (2025) 146 (Supplement 1): 1086.

https://doi.org/10.1182/blood-2025-1086

Published: 2025

Journal Articles

Characteristics and outcomes of non-transplanted newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) with once-weekly bortezomib dosing

Laahn Foster, Xin Yin, Eric Chinaeke, Jinghua He, Vipin Khare, Annelore Cortoos, Rohan Medhekar, Natalia Neparidze

Blood (2025) 146 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2025-2791

Published: 2025

Journal Articles

Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma

Amy Huang, Nicole Sequeira, Anthony Zhang, Ursula Medeiros Araujo de Matos, Elan Gorshein, Talib Dosani, Ritika Vankina, Syed Ali, Natalia Neparidze, Swarup Kumar

Blood (2025) 146 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2025-4567

Published: 2025

Journal Articles

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7831.

https://doi.org/10.1182/blood-2024-204150

Published: 2024

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)

Poy Theprungsirikul, Rong Wang, Man-Yee Merl, Shi-Yi Wang, Natalia Neparidze

Blood (2024) 144 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2024-201603

Published: 2024

Journal Articles

Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study

Poy Theprungsirikul, Yuxin Liu, Natalia Neparidze

Blood (2023) 142 (Supplement 1): 7364.

https://doi.org/10.1182/blood-2023-186985

Published: 2023

Journal Articles

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Sabrina L. Browning, Allison J. Li, Terri L. Parker, Noffar Bar, Tara Anderson, Erica Stevens, Yuxin Liu, Martin Matthews, Jennifer VanOudenhove, Rebecca Cardone, Qiushi Sun, Robert Hale, Stephanie Halene, Richard Kibbey, Natalia Neparidze

Blood (2023) 142 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2023-186401

Published: 2023

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders

Sean X Gu, Patrick G Gallagher, Ayesha Butt, Vivian W Gu, Kimberly Lezon-Geyda, Vincent P Schulz, Stephanie Prozora, Alfred I Lee, Natalia Neparidze, Noffar Bar, Kelsey Martin, Jennifer Cornell, Giavanna Chirico, Raja Chakraborty, Henry M Rinder, John Hwa, Robert D Bona

Blood (2023) 142 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2023-177946

Published: 2023

Journal Articles

A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma

Natalia Neparidze, Amandeep Godara, Dee Lin, Hoa H. Le, Karen Fixler, Lisa Shea, Stephanie Everson, Christine Brittle, Kimberly Brunisholz

Blood (2023) 142 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2023-178893

Published: 2023

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Blood (2022) 140 (Supplement 1): 7315–7316.

https://doi.org/10.1182/blood-2022-164966

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev

Blood (2022) 140 (Supplement 1): 11004–11006.

https://doi.org/10.1182/blood-2022-165156

Published: 2022

Journal Articles

Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma

Rong Wang, Natalia Neparidze, Xiaomei Ma, Graham A Colditz, Su-Hsin Chang, Shi-Yi Wang

Blood (2022) 140 (Supplement 1): 5270–5271.

https://doi.org/10.1182/blood-2022-164741

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Characteristics and outcomes of non-transplanted newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) with once-weekly bortezomib dosing

Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)

Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders

A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only